Value based pricing could cost the NHS more


The planned new value based pricing system for approving drugs to be funded by the NHS could end up costing the NHS more, the Department of Health’s own impact assessment states.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here